drugset / Trial / NCT01592214

Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73

NCT01592214 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase I, multi-center, clinical study of XF-73 to evaluate the local (nasal) safety and tolerability of a modified, thinner lower viscosity formulation of intranasal XF-73 in healthy male and female subjects. In addition, the potential for systemic absorption of XF-73 in the modified, thinner lower viscosity and the previously investigated thicker, higher viscosity formulations and their decolonization efficacy in comparison to placebo will be evaluated. Both parts of the study will be double-blinded and Part 2 will also be placebo-controlled. Primary objective is to establish the safety and tolerability of two concentrations of a modified thinner, lower viscosity nasal formulation of XF-73 and to compare them to a previously investigated, thicker, higher viscosity formulation

Timeline

Start
2012-08
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject EXEPORFINIUM Other / unclassified 0.6 mg Intranasal
Subject EXEPORFINIUM Other / unclassified 2.4 mg Intranasal